Este informe no está disponible en español.
P&G Pharmaceuticals Adds $30 Million Facility To Manati Plant
BY MARIALBA MARTINEZ
November 23, 2000
Procter & Gamble (P&G) Pharmaceuticals Puerto Rico Inc. has invested $30 million in a dose form facility to their Manati plant, said Ramon Sepulveda, general manager and vice president of the pharmaceutical company.
"We will produce two new products in this area. One of them is Actonel, used for the treatment and prevention of osteoporosis. The drug is already approved by the Food and Drug Administration (FDA) and ready for production. We expect a second drug permit to be approved by early December," said Sepulveda.
In 1994, P&G Pharmaceuticals underwent a global restructuring of its operations. The company transferred some of its manufacturing operations volume to other sites and reduced the number of employees.
"But Puerto Rico is still seen as an attractive operation. The 30,000 square feet just added complement the existing 105,000 square feet of space we originally had. Our systems and treatment plants have also been upgraded and within the next three to five years we expect to have finished upgrading the entire building," said Sepulveda.
In preparation for the new expansion, 50 new jobs were added between 1999 and 2000. Within the next two years, the company expects to add 50 more people to their current workforce of 1,000.
This Caribbean Business article appears courtesy of Casiano Communications.